GAP-134 Hydrochloride, also known as Danegaptide Hydrochloride or ZP 1609 Hydrochloride, is primarily investigated for its potential therapeutic applications in cardiovascular diseases. It is a gap junction modifier, which plays a significant role in maintaining cellular communication, particularly in cardiac tissues. This compound has shown promise in preclinical studies for its ability to reduce myocardial injury and improve cardiac function following ischemic events, such as heart attacks. By enhancing gap junction communication, it may help in preserving the integrity of heart tissue and preventing arrhythmias. Additionally, it is being explored for its potential use in other conditions where cellular communication is disrupted, such as certain types of tissue damage or degenerative diseases. Research continues to evaluate its efficacy and safety in clinical settings.